Hidetoshi Kuruma

Tomitahama Hospital — Japan

Medicine · Health Sciences

20h-index1.6kcitations120works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(72), Estrogen and related hormone effects(33), Cancer, Lipids, and Metabolism(19), Clusterin in disease pathology(17), Prostate Cancer Diagnosis and Treatment(13)

Publications120 total

Real-world outcomes of prostate-specific membrane antigen-targeted radioligand therapy in Japanese patients with metastatic castration-resistant prostate cancer
Japanese Journal of Clinical Oncology·2025Open Access
Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
Prostate Cancer and Prostatic Diseases·2025· 2 citedOpen Access
Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga/F-PSMA PET/CT
Annals of Nuclear Medicine·2025· 2 cited
Comparison of Diagnostic Performance Between Manual Diagnosis Following PROMISE V2 and aPROMISE Utilizing Ga/F-PSMA PET-CT
2025Open Access
Data from Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression <i>In vivo</i>
2023Open Access
Supplementary Table 1 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression <i>In vivo</i>
2023Open Access
Supplementary Table S3 from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
2023Open Access
Supplementary Table S1 from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
2023Open Access
Supplementary Table 3 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table 3 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table S4 from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
2023Open Access
Supplementary Figure Legends from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table 5 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table 1 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 1 from Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression <i>In vivo</i>
2023Open Access
Supplementary Figure 2 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 1 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table S1 from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Shin Egawa(21), Martin Gleave(16), Amina Zoubeidi(16), Ladan Fazli(10), Takahiro Kimura(10), Kenta Miki(9), François Lamoureux(8), Christian Thomas(8), Norihiro Hayashi(8), Hiroshi Sasaki(8), Shiro Baba(8), Masaki Shiota(7), Eliana Beraldi(7), Hiroyuki Takahashi(7), Hiroaki Matsumoto(5), Yuko Kamata(5), Kazumasa Matsumoto(5), Masahito Kido(5), Ario Takeuchi(4), Min-Jean Yin(4)